No Data
No Data
No Data
No Data
No Data
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
BenzingaApr 19 09:28 ET
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
Seeking AlphaApr 19 06:13 ET
Express News | 2Seventy Bio Said Co, Bristol Myers Squibb Announced That FDA Approved Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma
Moomoo 24/7Apr 9 07:06 ET
2seventy Bio Is Maintained at Buy by Citigroup
2seventy Bio Is Maintained at Buy by Citigroup
Dow JonesApr 8 18:23 ET
Express News | Citigroup Maintains Buy on 2seventy Bio, Raises Price Target to $12
Moomoo 24/7Apr 8 18:12 ET
2seventy Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 118.18% Citigroup $9 → $12 Maintains Buy 03/18/2024 -9.09% Wedbush → $5 Reiterates Neutral → Ne
BenzingaApr 8 18:11 ET
71129854 : Looking like market already factored approval?
TrytosaveabitOP 71129854: Well some of the move is from other PR! And this approval isn’t huge because it was already approved, this is just allowing them to use it earlier in disease treatment! Still decent because they can use more sooner! Hehehe
71129854 : I agree, hopefully we get some bigger news here soon
No Data
No Data
Ginvest : Thank you for the timely info